Lenvatinib plus anti-PD-1 therapy represents a feasible conversion resection strategy for patients with initially unresectable hepatocellular carcinoma: A retrospective study

Lenvatinib plus anti-PD-1 therapy represents a feasible conversion resection strategy for patients with initially unresectable hepatocellular carcinoma: A retrospective study

PurposeWe aimed to investigate the feasibility of lenvatinib plus anti-PD-1 therapy as a conversion therapy for initially unresectable hepatocellular carcinoma (HCC).MethodsPatients with initially unresectable HCC who received combined lenvatinib and anti-PD-1 antibody between May 2020 and Jan 2022...

Full description

Bibliographic Details
Main Authors: Yong Yi, Bao-Ye Sun, Jia-Lei Weng, Cheng Zhou, Chen-Hao Zhou, Ming-Hao Cai, Jing-Yun Zhang, Hong Gao, Jian Sun, Jian Zhou, Jia Fan, Ning Ren, Shuang-Jian Qiu
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-11-01
Series:Frontiers in Oncology
Subjects:
hepatocellular carcinoma
lenvatinib
Anti-PD-1 therapy
conversion resection
objective response
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.1046584/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.1046584/full

Similar Items